Susanna A Mccolley

List of Publications by Year in Descending Order

106 papers	6,927 citations	36 h-index	83 g-index
124 ext. papers	8,452 ext. citations	7.4 avg, IF	5.74 L-index

#	Paper	IF	Citations
106	A rare case of pancytopenia in a child with cystic fibrosis: Can copper cure it all?. *Pediatric Pulmonology*, **2022**, 57, 317-319	3.5	
105	Cystic Fibrosis Diagnosis, Genetics and Lifelong Effects **2022**, 146-160		
104	Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID). *Journal of Cystic Fibrosis*, **2021**, 20, 810-819	4.1	10
103	Soft, skin-interfaced sweat stickers for cystic fibrosis diagnosis and management. *Science Translational Medicine*, **2021**, 13,	17.5	21
102	A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One Allele. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 1522-1532	10.2	30
101	Comment on Munck et al., Feb, 2021. *Journal of Cystic Fibrosis*, **2021**, 20, 717-718	4.1	2
100	Preferences for disclosing adverse childhood experiences for children and adults with cystic fibrosis. *Pediatric Pulmonology*, **2021**, 56, 921-927	3.5	0
99	Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. *Pediatric Pulmonology*, **2021**, 56, 1496-1503	3.5	16
98	Pancytopenia in a child with cystic fibrosis and severe copper deficiency: Insight from bone marrow evaluation. *Pediatric Blood and Cancer*, **2021**, 68, e29276	3	
97	Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study. *Lancet Respiratory Medicine,the*, **2021**, 9, 977-988	35.1	7
96	Outcomes of infants born during the first 9 years of CF newborn screening in the United States: A retrospective Cystic Fibrosis Foundation Patient Registry cohort study. *Pediatric Pulmonology*, **2021**, 56, 3758-3767	3.5	3
95	Finding the relevance of antimicrobial stewardship for cystic fibrosis. *Journal of Cystic Fibrosis*, **2020**, 19, 511-520	4.1	5
94	Tolerance of 7% Hypertonic Saline in Pediatric Cystic Fibrosis Patients. *Pediatric, Allergy, Immunology, and Pulmonology*, **2020**, 33, 63-68	0.8	78
93	Quantity not sufficient rates and delays in sweat testing in US infants with cystic fibrosis. *Pediatric Pulmonology*, **2020**, 55, 3053-3056	3.5	3
92	Cystic fibrosis year in review 2019: Section 1 CFTR modulators. *Pediatric Pulmonology*, **2020**, 55, 3236-3242	3.5	2
91	Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. *Lancet Respiratory Medicine,the*, **2019**, 7, 325-335	35.1	63
90	Cystic fibrosis year in review 2018, part 2. *Pediatric Pulmonology*, **2019**, 54, 1129-1140	3.5	1

89	Cystic fibrosis year in review 2018, part 1. *Pediatric Pulmonology*, **2019**, 54, 1117-1128	3.5	4
88	Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. *Clinical Infectious Diseases*, **2019**, 69, 1812-1816	11.6	33
87	Inconclusive diagnosis after a positive newborn bloodspot screening result for cystic fibrosis; clarification of the harmonised international definition. *Journal of Cystic Fibrosis*, **2019**, 18, 778-780	4.1	17
86	Transcriptome Profiling and Molecular Therapeutic Advances in Cystic Fibrosis: Recent Insights. *Genes*, **2019**, 10,	4.2	8
85	Cystic fibrosis and portal hypertension: Distal splenorenal shunt can prevent the need for future liver transplant. *Journal of Pediatric Surgery*, **2019**, 54, 1076-1082	2.6	7
84	Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV. *Journal of Cystic Fibrosis*, **2019**, 18, 94-101	4.1	26
83	Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet Respiratory Medicine,the*, **2019**, 7, 802-809	35.1	34
82	Microarray profiling identifies extracellular circulating miRNAs dysregulated in cystic fibrosis. *Scientific Reports*, **2019**, 9, 15483	4.9	17
81	The demographics of adverse outcomes in cystic fibrosis. *Pediatric Pulmonology*, **2019**, 54 Suppl 3, S74-S83	3.5	9
80	Identification of molecular signatures of cystic fibrosis disease status with plasma-based functional genomics. *Physiological Genomics*, **2019**, 51, 27-41	3.6	8
79	Are children with chronic illnesses requiring dietary therapy at risk for disordered eating or eating disorders? A systematic review. *International Journal of Eating Disorders*, **2018**, 51, 187-213	6.3	29
78	The relationship between sweat chloride levels and mortality in cystic fibrosis varies by individual genotype. *Journal of Cystic Fibrosis*, **2018**, 17, 34-42	4.1	10
77	Cystic fibrosis year in review 2017. *Pediatric Pulmonology*, **2018**, 53, 1307-1317	3.5	1
76	Designing trials for new cystic fibrosis modulators. *Lancet Respiratory Medicine,the*, **2018**, 6, 484-486	35.1	1
75	Ivacaftor treatment of cystic fibrosis in children aged 12 to . *Lancet Respiratory Medicine,the*, **2018**, 6, 545-553	35.1	112
74	Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities. *Journal of Clinical and Translational Science*, **2018**, 2, 334-342	0.4	11
73	Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. *Journal of Pediatrics*, **2017**, 181S, S4-S15.e1	3.6	368
72	Aminoglycoside resistance of Pseudomonas aeruginosa in cystic fibrosis results from convergent evolution in the mexZ gene. *Thorax*, **2017**, 72, 40-47	7.3	30

71	Diagnosis of Cystic Fibrosis in Screened Populations. *Journal of Pediatrics*, **2017**, 181S, S33-S44.e2	3.6	60
70	Risk factors for mortality before age 18 years in cystic fibrosis. *Pediatric Pulmonology*, **2017**, 52, 909-915	3.5	44
69	Cystic fibrosis year in review 2016. *Pediatric Pulmonology*, **2017**, 52, 1092-1102	3.5	6
68	Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. *Lancet Respiratory Medicine,the*, **2017**, 5, 557-567	35.1	176
67	Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 1144-1151	10.2	61
66	Antibiotic duration and changes in FEV are not associated with time until next exacerbation in adult cystic fibrosis: a single center study. *BMC Pulmonary Medicine*, **2017**, 17, 160	3.5	1
65	The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis. *Expert Opinion on Drug Safety*, **2017**, 16, 1305-1311	4.1	27
64	Airway microbiota across age and disease spectrum in cystic fibrosis. *European Respiratory Journal*, **2017**, 50,	13.6	113
63	Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR. *Annals of the American Thoracic Society*, **2017**, 14, 213-219	4.7	57
62	Minorities Are Underrepresented in Clinical Trials of Pharmaceutical Agents for Cystic Fibrosis. *Annals of the American Thoracic Society*, **2016**, 13, 1721-1725	4.7	28
61	Refining the continuum of CFTR-associated disorders in the era of newborn screening. *Clinical Genetics*, **2016**, 89, 539-49	4	24
60	A safety evaluation of ivacaftor for the treatment of cystic fibrosis. *Expert Opinion on Drug Safety*, **2016**, 15, 709-15	4.1	15
59	Combination lumacaftor and ivacaftor therapy for cystic fibrosis. *Expert Opinion on Orphan Drugs*, **2016**, 4, 233-242	1.1	2
58	Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. *Journal of Pediatrics*, **2016**, 169, 116-21.e2	3.6	33
57	Pediatric Pulmonology year in review 2015: Part 4. *Pediatric Pulmonology*, **2016**, 51, 754-65	3.5	
56	Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. *Lancet Respiratory Medicine,the*, **2015**, 3, 524-33	35.1	161
55	Outcomes of infants with indeterminate diagnosis detected by cystic fibrosis newborn screening. *Pediatrics*, **2015**, 135, e1386-92	7.4	52
54	2014 year in review: Cystic fibrosis. *Pediatric Pulmonology*, **2015**, 50, 1147-56	3.5	1

53	Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. *New England Journal of Medicine*, **2015**, 373, 220-31	59.2	910
52	Disparities in Parental Health Literacy at a Pediatric Cystic Fibrosis Center. *Pediatric, Allergy, Immunology, and Pulmonology*, **2015**, 28, 55-59	0.8	3
51	A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. *Lancet Respiratory Medicine,the*, **2014**, 2, 527-38	35.1	309
50	Pancreatic enzyme replacement therapy dosing and nutritional outcomes in children with cystic fibrosis. *Journal of Pediatrics*, **2014**, 164, 1110-1115.e1	3.6	32
49	Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet Respiratory Medicine,the*, **2014**, 2, 539-47	35.1	242
48	Trichosporon mycotoxinivorans infection in patients with cystic fibrosis. *Journal of Clinical Microbiology*, **2014**, 52, 2242-4	9.7	17
47	Primary Snoring **2014**, 209-214		
46	Ivacaftor therapy for cystic fibrosis. *Expert Opinion on Orphan Drugs*, **2014**, 2, 1225-1232	1.1	2
45	Sustained improvement in nutritional outcomes at two paediatric cystic fibrosis centres after quality improvement collaboratives. *BMJ Quality and Safety*, **2014**, 23 Suppl 1, i81-9	5.4	11
44	Improved patient safety through reduced airway infection rates in a paediatric cystic fibrosis programme after a quality improvement effort to enhance infection prevention and control measures. *BMJ Quality and Safety*, **2014**, 23 Suppl 1, i73-i80	5.4	11
43	Update in pediatric lung disease 2012. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 293-7	10.2	3
42	Update in cystic fibrosis 2011. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 185, 933-6	10.2	9
41	Hispanic Infants with cystic fibrosis show low CFTR mutation detection rates in the Illinois newborn screening program. *Journal of Genetic Counseling*, **2012**, 21, 671-5	2.5	13
40	Update in pediatric lung disease 2011. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 186, 30-4	10.2	1
39	Lung function decline from adolescence to young adulthood in cystic fibrosis. *Pediatric Pulmonology*, **2012**, 47, 135-43	3.5	77
38	Risk factors for onset of persistent respiratory symptoms in children with cystic fibrosis. *Pediatric Pulmonology*, **2012**, 47, 966-72	3.5	12
37	Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 185, 171-8	10.2	97
36	Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis. *Journal of Pediatrics*, **2011**, 159, 819-824.e1	3.6	27

35	Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. *Pediatric Pulmonology*, **2011**, 46, 36-44	3.5	69
34	Elevated vascular endothelial growth factor is correlated with elevated erythropoietin in stable, young cystic fibrosis patients. *Pediatric Pulmonology*, **2011**, 46, 683-7	3.5	13
33	Clinical significance of microbial infection and adaptation in cystic fibrosis. *Clinical Microbiology Reviews*, **2011**, 24, 29-70	34	271
32	Parental understanding of newborn screening for cystic fibrosis after a negative sweat-test. *Pediatrics*, **2011**, 127, 276-83	7.4	22
31	Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 182, 298-306	10.2	158
30	The need for quality improvement in sweat testing infants after newborn screening for cystic fibrosis. *Journal of Pediatrics*, **2010**, 157, 1035-7	3.6	29
29	Pediatric respiratory medicine--an international perspective. *Pediatric Pulmonology*, **2010**, 45, 14-24	3.5	6
28	Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis. *Journal of Pediatrics*, **2009**, 155, 634-9.e1-4	3.6	73
27	Increased prevalence of risk factors for morbidity and mortality in the US Hispanic CF population. *Pediatric Pulmonology*, **2009**, 44, 594-601	3.5	30
26	EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. *Journal of Cystic Fibrosis*, **2009**, 8, 405-17	4.1	47
25	Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: a paradigm of chronic infection. *Translational Research*, **2008**, 152, 257-64	11	36
24	Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function. *Pediatrics*, **2007**, 119, e531-7	7.4	48
23	A day in the life of a nebulizer: surveillance for bacterial growth in nebulizer equipment of children with cystic fibrosis in the hospital setting. *Respiratory Care*, **2007**, 52, 258-62	2.1	22
22	ATS Consensus Statement: Research opportunities and challenges in pediatric pulmonology. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 172, 776-80	10.2	11
21	Primary Snoring in Children **2005**, 263-267		1
20	Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis. *Journal of Clinical Microbiology*, **2004**, 42, 5229-37	9.7	154
19	Treatment of plastic bronchitis in a Fontan patient with tissue plasminogen activator: a case report and review of the literature. *Pediatrics*, **2002**, 109, e67	7.4	73
18	Clinical practice guideline: diagnosis and management of childhood obstructive sleep apnea syndrome. *Pediatrics*, **2002**, 109, 704-12	7.4	753

17	Postexercise immune correlates in children with and without cystic fibrosis. *Medicine and Science in Sports and Exercise*, **2000**, 32, 1997-2004	1.2	4
16	Serum vascular endothelial growth factor is elevated in cystic fibrosis and decreases with treatment of acute pulmonary exacerbation. *American Journal of Respiratory and Critical Care Medicine*, **2000**, 161, 1877-80	10.2	72
15	Immune modulation following aerobic exercise in children with cystic fibrosis. *International Journal of Sports Medicine*, **2000**, 21, 294-301	3.6	9
14	Parental attitudes about exercise regarding their children with cystic fibrosis. *International Journal of Sports Medicine*, **1999**, 20, 334-8	3.6	5
13	Energy metabolism during anaerobic exercise in children with cystic fibrosis and asthma. *Medicine and Science in Sports and Exercise*, **1999**, 31, 1242-9	1.2	15
12	Bronchopulmonary dysplasia. Impact of surfactant replacement therapy. *Pediatric Clinics of North America*, **1998**, 45, 573-86	3.6	10
11	Wheezing or stridor: intrinsic and extrinsic lesions causing noisy breathing. *Allergy and Asthma Proceedings*, **1998**, 19, 81-4	2.6	2
10	High prevalence of allergic sensitization in children with habitual snoring and obstructive sleep apnea. *Chest*, **1997**, 111, 170-3	5.3	163
9	Polysomnography in the evaluation of readiness for decannulation in children. *JAMA Otolaryngology*, **1996**, 122, 721-4		38
8	Polysomnography after adenotonsillectomy in mild pediatric obstructive sleep apnea. *Critical Care Medicine*, **1996**, 24, 1323-7	1.4	65
7	Immune response to influenza vaccination in children with renal disease. *Pediatric Nephrology*, **1995** , 9, 566-8	3.2	46
6	Inability of clinical history to distinguish primary snoring from obstructive sleep apnea syndrome in children. *Chest*, **1995**, 108, 610-8	5.3	502
5	Upper airway collapsibility in children with obstructive sleep apnea syndrome. *Journal of Applied Physiology*, **1994**, 77, 918-24	3.7	197
4	Polysomnographic characteristics of patients with Rett syndrome. *Journal of Pediatrics*, **1994**, 125, 218-24	3.6	68
3	Respiratory compromise after adenotonsillectomy in children with obstructive sleep apnea. *JAMA Otolaryngology*, **1992**, 118, 940-3		287
2	Differences in expression of cystic fibrosis in blacks and whites. *JAMA Pediatrics*, **1991**, 145, 94-7		7
1	Effect of oxygenation on breath-by-breath response of the genioglossus muscle during occlusion. *Journal of Applied Physiology*, **1991**, 71, 1231-6	3.7	14